Delgocitinib Cream (Anzupgo) for Chronic Hand Eczema
Delgocitinib Cream (Anzupgo) for Chronic Hand Eczema
October 13, 2025 (Issue: 1739)
The FDA has approved a 2% cream formulation of
delgocitinib (Anzupgo – Leo), a Janus kinase (JAK)
inhibitor, for treatment of moderate to severe chronic
hand eczema (dermatitis) in adults who had an
inadequate response to or are unable to use...more
- Ruxolitinib (Opzelura) for atopic dermatitis. Med Lett Drugs Ther 2022; 64:12.
- JP Thyssen et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis 2022; 86:357. doi:10.1111/cod.14035
- E Weisshaar. Chronic hand eczema. Am J Clin Dermatol 2024; 25:909. doi:10.1007/s40257-024-00890-z
- EL Simpson et al. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2024; 90:1190. doi:10.1016/j.jaad.2023.12.066
- R Bissonnette et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet 2024; 404:461. doi:10.1016/s0140-6736(24)01027-4
- M Gooderham et al. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol 2025; 93:95. doi:10.1016/j.jaad.2025.03.008
- AM Giménez-Arnau et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial. Lancet 2025; 405:1676. doi:10.1016/s0140-6736(25)00001-7
- In brief: New warnings for Janus kinase inhibitors. Med Lett Drugs Ther 2021; 63:160.
- Approximate WAC for a 30-gram tube. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. September 5, 2025. Reprinted with permission by First Databank, Inc. All rights reserved. ©2025. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Delgocitinib Cream (Anzupgo) for Chronic Hand Eczema
Article code: 1739b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
